Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia - Related Studies

Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

This study is ongoing, but not recruiting participants.

Study NCT00003407. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cancer-Related Problem/Condition
		Leukemia
		Myelodysplastic Syndromes

2	Additional conditions recognized in this trial
		Leukemia, Myelogenous, Chronic, BCR-ABL Positive
		Leukemia, Myeloid
		Leukemia, Myeloid, Acute
		Preleukemia
		Syndrome

3	More general conditions related to this trial
		Bone Marrow Diseases
		Disease
		Hematologic Diseases
		Myeloproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Pathologic Processes
		Precancerous Conditions

4	Interventions listed in this trial
		amifostine trihydrate
		cytarabine
		mitoxantrone hydrochloride

5	Additional drug interventions recognized in this trial
		Amifostine
		Mitoxantrone

6	More general drug interventions related to this trial
		Analgesics
		Anti-Infective Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antiviral Agents
		Central Nervous System Agents
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protective Agents
		Radiation-Protective Agents
		Sensory System Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		Rush University Medical Center
		National Cancer Institute (NCI)